Percentage of women who reported specific adverse events during clinical trials of hormonal contraceptive methods
| AE | Contraceptive | AE frequency (%) | Sample size (n) | Publication |
| Sore breasts | COC | 8.3 | 2837 | Yasmin12 |
| COC | 3.8 | 2501 | NuvaRing17 | |
| IUS | 8.5* | 5091 | Mirena15 | |
| Injection | 2.8 | >3900 | Depo-Provera16 | |
| Nausea/vomiting | COC | 4.5 | 2837 | Yasmin12 |
| COC | 16.3 | 1723 | Ortho Tri-Cyclen Lo11 | |
| Injection | 3.3 | >3900 | Depo-Provera16 | |
| Transdermal system | 16.6 | 3322 | Ortho Evra18 | |
| Vaginal ring | 5.9 | 2501 | NuvaRing17 | |
| Changes in premenstrual syndrome | COC | 13.2 | 2837 | Yasmin12 |
| Vaginal discharge | IUS | 14.9* | 5091 | Mirena15 |
| Vaginal ring | 5.7 | 2501 | NuvaRing17 | |
| Alteration of menstrual bleeding patterns | IUS | 31.9* | 5091 | Mirena15 |
| Vulvovaginitis | IUS | 10.5* | 5091 | Mirena15 |
| Back pain | IUS | 7.9* | 5091 | Mirena15 |
| Dysmenorrhea | Vaginal ring | 3.5 | 2501 | NuvaRing17 |
| COC | 6.4* | 5091 | Mirena15 | |
| Injection | 1.7 | >3900 | Depo-Provera16 | |
| Transdermal system | 7.8 | 3322 | Ortho Evra18 |
*Crude incidence per person-years.
AE, adverse event; COC, combined oral contraceptive; IUS, intrauterine system.